Skip to main content
Premium Trial:

Request an Annual Quote

AB Sciex Acquires Eksigent's LC Business

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AB Sciex has acquired the liquid chromatography business of Eksigent Technologies for an undisclosed amount, the firm said today.

The acquired technologies complement AB Sciex's mass spectrometry business and provide the firm with an entry into the LC market. Among the acquired products are Eksigent's NanoLC-Ultra System for proteomics, the cHiPLC-nanoflex System for protein peptide separations, and the ExpressHT-Ultra HPLC System for LC/MS studies of pharmacokinetics and drug metabolism.

In addition to the acquired technologies, AB Sciex gains approximately 50 employees in Eksigent's R&D, manufacturing, and sales operations, located in Dublin, Calif.

"Eksigent's portfolio of HPLC technologies is among the most innovative within the industry and is extremely complementary to our market-leading mass spectrometry systems," AB Sciex President Andy Boorn, said in a statement. "We expect to further develop and broaden the use of these technologies for a variety of life science applications."

AB Sciex is a subsidiary of Danaher, following that firm's recent purchase of MDS Analytical Technologies — including the mass spec joint venture with Life Technologies — for $1.1 billion.

Boorn was named a president of the firm along with Laura Lauman, formerly the head of mass spec for Life Technologies. Following its recent launch as AB Sciex, Lauman said during a conference call that the new corporate structure "enables us to make strategic investments and partnerships as well as identify and acquire emerging technologies that are complementary to our business."

"Danaher is a large company that's known for expanding its portfolio, and that is something we'll consider as well," she added.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.